The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida
暂无分享,去创建一个
Russell E. Lewis | D. Kontoyiannis | Dimitrios P. Kontoyiannis | Pierluigi Viale | P. Viale | R. Lewis
[1] M. Pfaller,et al. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.
[2] N. Wiederhold. Paradoxical echinocandin activity: a limited in vitro phenomenon? , 2009, Medical mycology.
[3] B. Wickes,et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. , 2002, The Journal of antimicrobial chemotherapy.
[4] D. Kontoyiannis,et al. Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies , 2008, Antimicrobial Agents and Chemotherapy.
[5] M. Jacobsen,et al. Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection , 2010, Antimicrobial Agents and Chemotherapy.
[6] B. Hube,et al. Interaction of pathogenic yeasts with phagocytes: survival, persistence and escape. , 2010, Current opinion in microbiology.
[7] D. Andes,et al. Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene , 2010, Antimicrobial Agents and Chemotherapy.
[8] Russell E. Lewis,et al. Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences , 2007, Antimicrobial Agents and Chemotherapy.
[9] B. Posteraro,et al. Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice , 2011, Antimicrobial Agents and Chemotherapy.
[10] G. Fadda,et al. Role of AFR1, an ABC Transporter-Encoding Gene, in the In Vivo Response to Fluconazole and Virulence of Cryptococcus neoformans , 2006, Infection and Immunity.
[11] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] L. Bopp,et al. Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. , 2006, Journal of medical microbiology.
[13] Ronald N. Jones,et al. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). , 2010, Diagnostic microbiology and infectious disease.
[14] Y. Okawa,et al. Significant differences in the cell‐wall mannans from three Candida glabrata strains correlate with antifungal drug sensitivity , 2012, The FEBS journal.
[15] D. Lawrence,et al. Effects of echinocandins on cytokine/chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide. , 2012, Diagnostic microbiology and infectious disease.
[16] E. Anaissie,et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] L. Bopp,et al. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. , 2008, The Journal of antimicrobial chemotherapy.
[18] T. C. White,et al. Studies of the paradoxical effect of caspofungin at high drug concentrations. , 2005, Diagnostic microbiology and infectious disease.
[19] D. Kontoyiannis,et al. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. , 2008, Medical mycology.
[20] S. Kelly,et al. Azole Resistance by Loss of Function of the Sterol Δ5,6-Desaturase Gene (ERG3) in Candida albicans Does Not Necessarily Decrease Virulence , 2012, Antimicrobial Agents and Chemotherapy.
[21] D. Denning. Echinocandin antifungal drugs , 2003, The Lancet.
[22] D. Kontoyiannis,et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. , 2011, The Journal of infectious diseases.
[23] D. Andes,et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. , 2007, Antimicrobial agents and chemotherapy.
[24] D. Marriott,et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[25] S. Smeekens,et al. The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis , 2011, European journal of immunology.
[26] K. Bartizal,et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies , 1996, Infection and immunity.
[27] J. Graybill,et al. Fluconazole versus Candida albicans: A Complex Relationship , 1998, Antimicrobial Agents and Chemotherapy.
[28] D. Stevens,et al. Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for β-1,6-Glucan Synthesis Inhibition by Caspofungin , 2006, Antimicrobial Agents and Chemotherapy.
[29] M. Netea,et al. An integrated model of the recognition of Candida albicans by the innate immune system , 2008, Nature Reviews Microbiology.
[30] G. Kardos,et al. In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin , 2010, The Journal of Microbiology.
[31] M. Borg-von Zepelin,et al. Difference in virulence between fluconazole‐susceptible and fluconazole‐resistant Candida albicans in a mouse model , 2011, Mycoses.
[32] K. Kuchler,et al. The Facultative Intracellular Pathogen Candida glabrata Subverts Macrophage Cytokine Production and Phagolysosome Maturation , 2011, The Journal of Immunology.
[33] C. Munro,et al. Fungal echinocandin resistance , 2010, F1000 biology reports.
[34] N. Gow,et al. Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo , 2011, Antimicrobial Agents and Chemotherapy.
[35] L. Romani. Immunity to fungal infections , 2004, Nature Reviews Immunology.
[36] M. Zupancic,et al. A yeast by any other name: Candida glabrata and its interaction with the host. , 2005, Current opinion in microbiology.
[37] C. Clancy,et al. Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum , 2011, Antimicrobial Agents and Chemotherapy.
[38] J. Sobel,et al. Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.
[39] G. Fadda,et al. Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence , 2009, PLoS pathogens.
[40] N. Gow,et al. Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins , 2008, PLoS pathogens.
[41] J. Latgé,et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence , 2012, Nature Communications.
[42] M. Netea,et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. , 2002, The Journal of infectious diseases.
[43] R. Homayouni,et al. Genome-Wide Expression Profiling of the Response to Azole, Polyene, Echinocandin, and Pyrimidine Antifungal Agents in Candida albicans , 2005, Antimicrobial Agents and Chemotherapy.
[44] K. Kuchler,et al. Candida glabrata Persistence in Mice Does Not Depend on Host Immunosuppression and Is Unaffected by Fungal Amino Acid Auxotrophy , 2009, Infection and Immunity.
[45] Russell E. Lewis,et al. Attenuation of the Activity of Caspofungin at High Concentrations against Candida albicans: Possible Role of Cell Wall Integrity and Calcineurin Pathways , 2005, Antimicrobial Agents and Chemotherapy.
[46] B. Maras,et al. Identification of Major Glucan-Associated Cell Wall Proteins of Candida albicans and Their Role in Fluconazole Resistance , 2002, Antimicrobial Agents and Chemotherapy.
[47] M. Pfaller,et al. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.
[48] D. Andes,et al. Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance , 2006, Antimicrobial Agents and Chemotherapy.
[49] T. Patterson,et al. Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans , 2011, Antimicrobial Agents and Chemotherapy.
[50] James B. Anderson. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness , 2005, Nature Reviews Microbiology.
[51] R. Filmon,et al. In-vivo selection of an azole-resistant petite mutant of Candida glabrata. , 2000, Journal of medical microbiology.
[52] D. Perlin. Antifungal drug resistance: do molecular methods provide a way forward? , 2009, Current opinion in infectious diseases.
[53] G. Fink,et al. A Drug-Sensitive Genetic Network Masks Fungi from the Immune System , 2006, PLoS pathogens.
[54] Duccio Cavalieri,et al. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans , 2011, Journal of leukocyte biology.
[55] D. MacCallum. Hosting Infection: Experimental Models to Assay Candida Virulence , 2011, International journal of microbiology.
[56] M. Laverdière,et al. Inactivation of Sterol Δ5,6-Desaturase Attenuates Virulence in Candida albicans , 2005, Antimicrobial Agents and Chemotherapy.
[57] Alistair J. P. Brown,et al. Candida albicans morphogenesis and host defence: discriminating invasion from colonization , 2011, Nature Reviews Microbiology.
[58] Steven D. Brown,et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[59] M. Laverdière,et al. Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans. , 2005, Antimicrobial agents and chemotherapy.
[60] L. Bopp,et al. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. , 2005, Diagnostic microbiology and infectious disease.
[61] A. Rodloff,et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion , 2010, Journal of Clinical Microbiology.
[62] E. Katchburian,et al. Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four Different Candida Species , 2010, Antimicrobial Agents and Chemotherapy.
[63] Gerald R. Fink,et al. Dynamic, Morphotype-Specific Candida albicans β-Glucan Exposure during Infection and Drug Treatment , 2008, PLoS pathogens.
[64] D. Sanglard,et al. Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata , 2001, Antimicrobial Agents and Chemotherapy.
[65] D. Perlin. Current perspectives on echinocandin class drugs. , 2011, Future microbiology.
[66] E. Anaissie,et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] M. Netea,et al. Toll-Like Receptor 2 Suppresses Immunity against Candida albicans through Induction of IL-10 and Regulatory T Cells , 2004, The Journal of Immunology.
[68] L. Cowen,et al. Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms , 2011, PLoS pathogens.
[69] Alexander D. Johnson,et al. A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans , 2012, Cell.
[70] M. Motyl,et al. Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome , 2005, Antimicrobial Agents and Chemotherapy.
[71] D. Kontoyiannis,et al. Resistance to echinocandins comes at a cost , 2012, Virulence.
[72] M. Castanheira,et al. Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata , 2012, Journal of Clinical Microbiology.
[73] M. Netea,et al. Recognition of fungal pathogens by Toll-like receptors , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[74] M. Netea,et al. Toll‐like receptors and the host defense against microbial pathogens: bringing specificity to the innate‐immune system , 2004, Journal of leukocyte biology.
[75] David W Williams,et al. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. , 2009, Medical mycology.
[76] M. Pfaller,et al. Epidemiology of Invasive Mycoses in North America , 2010, Critical reviews in microbiology.
[77] M. Netea,et al. Innate immune mechanisms for recognition and uptake of Candida species. , 2010, Trends in immunology.
[78] C. Hennequin,et al. Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.
[79] M. Ghannoum,et al. Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution , 2012, Journal of Clinical Microbiology.